Treatment with lisocabtagene maraleucel elicited encouraging responses regardless of prior progression on BTK inhibition or absence of clinical benefit with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, meeting the primary end point of the phase 1/2 TRANSCEND CLL 004 trial.
Nouscom today announced encouraging new translational data obtained from the ongoing Phase 1 trial evaluating NOUS-209. The data were presented yesterday
BASEL, Switzerland – 11th April 2022 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced encouraging new translational data obtained from the ongoing Phase 1 trial evaluating NOUS-209. The data were presented yesterday in.